Welgus Howard G. 4
4 · Arcutis Biotherapeutics, Inc. · Filed Oct 3, 2025
Insider Transaction Report
Form 4
Welgus Howard G.
Director
Transactions
- Sale
Common Stock
2025-10-01$18.92/sh−462$8,742→ 99,744 total - Sale
Common Stock
2025-10-01$18.92/sh−9,538$180,485→ 100,206 total - Exercise/Conversion
Common Stock
2025-10-01$1.68/sh+9,538$16,030→ 109,744 total - Exercise/Conversion
Stock Option (right to buy)
2025-10-01−9,538→ 0 totalExercise: $1.68Exp: 2029-03-13→ Common Stock (9,538 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This option is fully vested.